Disease Diagnosis TRIZ Cases

Anti-L1CAM antibody captures CNS-derived exosomes from peripheral blood for biomarker detection.

A hyaluronidase 2-binding agent detects elevated myeloid cells in blood samples.

Analyzing myeloid and T cell phenotypes resolves the lack of predictive models for cabozantinib response.

A diagnostic kit quantifies full-length and cleaved megalin fragments in urine using specific ligands to differentiate protein states.

Labeled antibodies targeting the DPP6 biomarker allow precise quantification of beta cell mass without invasive tissue sampling.

Detecting marker protein levels in biological samples predicts patient responsiveness to sublingual immunotherapy treatments.

Administering folic acid supplements alongside PARP inhibitors prevents hematologic toxicity caused by folate deficiency, enabling sustained cancer treatment.

Segmented nanobody format resolves low yield and side effects while enabling precise CD3ε targeting.

Density gradient ultracentrifugation isolates exosomes from plasma to identify tumor-specific cargoes, bypassing MRI false positives.

A solid support complex attaches multiple antigens via carrier proteins to capture diverse antibodies simultaneously.

Combining GDF-15 with NT-proBNP markers resolves diagnostic inaccuracies in atrial fibrillation patients.

Prothoracic gland genetic modification extends third instar duration, enabling long-term neurodegeneration and nerve regeneration studies.

A fluorescence immunochromatographic detection card uses fluorescent microspheres and a biotin-streptavidin system to detect biomarkers.

Serotonin receptor inhibitors selectively destroy acute myeloid leukemia cells while sparing healthy hematopoietic stem cells, reducing treatment toxicity.

Classifying patients via KLRG1 expression reduces unnecessary antiviral side effects while ensuring infection control for high-risk recipients.

Segmented ELISA detection of FCGBP, MRC1, and LBP biomarkers resolves diagnostic sensitivity limits while managing method complexity.

A serum biomarker panel measures specific protein levels to detect synovial joint disease in mucopolysaccharidoses.

Hybridoma-derived antibody detects feline cystatin C, resolving lack of specific reagents to enable rapid nephropathy diagnosis.

Apolipoprotein A-IV concentration in serum predicts chronic kidney disease progression through enzyme-linked immunosorbent assay detection.

Recombinant GM2A antibodies detect ganglioside GM2A protein levels to resolve the trade-off between diagnostic accuracy and patient invasiveness.

Full spectrum flow cytometry measures entire emission spectra to resolve overlapping fluorophores, enabling precise immune profiling from limited samples.

Detecting IgM and CXCL13 levels predicts NMOSD relapse risk, enabling targeted immunotherapy that reduces unnecessary side effects.

Segmenting multiple immune cell markers resolves the contradiction between early detection capability and diagnostic reliability for Parkinson's disease.

Analyzing eicosanoid levels in first-trimester blood samples enables reliable preeclampsia detection before gestational week 16.

Antibody-based lateral flow assays replace complex chromatography to enable cost-effective, high-throughput monitoring of risperidone levels.

Segmenting small dense LDL from other fractions with a separating agent to improve familial combined hyperlipidemia detection accuracy.

Polypeptide biomarker panels quantify Apo C-III and Serum Amyloid A concentrations to resolve sensitivity and specificity trade-offs in stroke diagnosis.

Oral lipids trigger cholecystokinin release to mobilize liver triglycerides, bypassing contraindicated drug therapies.